GLENDA GROVENBERRY: Open Payments
NPI 1295343689 · NOBLESVILLE, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$979 in 53 payments from 13 companies in 2025. Trend: 2023 $0 · 2024 $225 · 2025 $979
Food & beverage: $979
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 9 | $194 |
| Otsuka America Pharmaceutical, Inc. | 10 | $170 |
| E.R. Squibb & Sons, L.L.C. | 10 | $143 |
| Teva Pharmaceuticals USA, Inc. | 6 | $130 |
| Neurocrine BioSciences, Inc. | 4 | $91 |
| ABBVIE INC. | 4 | $59 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $58 |
| Janssen Pharmaceuticals, Inc | 2 | $38 |
| Azurity Pharmaceuticals, Inc. | 1 | $26 |
| Tris Pharma Inc | 1 | $21 |
Products named: ARISTADA, COBENFY, AUSTEDO XR, INGREZZA, ABILIFY ASIMTUFII, CAPLYTA, REXULTI, VRAYLAR.
Industry payments across IN — which companies pay providers there.
